Q2 2025 Vanda Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Fanapt revenue increased by 27% compared to the same period in the prior year, driven by the launch of the bipolar I indication.
- Total revenue from Vanda Pharmaceuticals Inc (VNDA)'s three commercial-branded products, Fanapt, HETLIOZ, and PONVORY, reached $102.6 million in the first six months of 2025.
- HETLIOZ continues to be the market share leader despite the availability of its generic products, demonstrating strong brand loyalty.
- The NDA for Bysanti for the acute treatment of bipolar one disorder and the treatment of schizophrenia was accepted for filing by the FDA with a PDUFA target action date of February 21, 2026.
- Vanda Pharmaceuticals Inc (VNDA) has a strong cash position with $325.6 million as of June 30, 2025, providing financial stability for future investments.
- HETLIOZ net product sales decreased by 4% compared to the same period in 2024, primarily due to a decrease in volume.
- PONVORY net product sales decreased by 18% compared to the same period in 2024, attributed to a decrease in volume and price net of deductions.
- Vanda Pharmaceuticals Inc (VNDA) recorded a net loss of $56.7 million for the first six months of 2025, compared to a net loss of $8.7 million for the same period in 2024.
- Operating expenses increased significantly by $64.8 million, primarily driven by higher SG&A expenses related to commercial launches and higher R&D expenses.
- HETLIOZ net product sales may decline in future periods due to continued generic competition in the US, potentially impacting revenue.
Good day, everyone, and thank you for standing by. My name is Argy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2025 Vanda Pharmaceuticals Inc.'s earnings conference call.
(Operator Instructions)
I would now like to turn the call over to Vanda's Chief Financial Officer, Kevin Moran. Please go ahead.
Great. Thank you, Argy. Good morning and thank you for joining us to discuss Vanda Pharmaceuticals' second-quarter 2025 performance. Our second-quarter 2025 results were released this morning and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.
Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board; and Tim Williams, our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
